<DOC>
	<DOCNO>NCT01268163</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetic safety characteristic European Taxotere® American Taxotere® Hospira Docetaxel injection patient cancer .</brief_summary>
	<brief_title>The Pharmacokinetics Safety Characteristics Docetaxel Patients With Cancer</brief_title>
	<detailed_description>No information available pharmacokinetic characteristic , safety efficacy Hospira Docetaxel Injection . The primary purpose study therefore compare pharmacokinetic characteristic 60-100 mg/m² Hospira Docetaxel Injection , 60-100 mg/m² European Taxotere® ( Taxotere® EU ) 60-100 mg/m² American Taxotere® ( Taxotere® US ) administer 1 hour intravenous infusion man . The secondary objective study compare safety tolerability Hospira Docetaxel Injection , Taxotere® EU Taxotere® US . The study also provide opportunity ass select efficacy endpoint accord local practice cycle treatment . The study dose regimen ( 60-100 mg/m² , administer 1 hour intravenous infusion 3 week interval ) subject population ( cancer patient Taxotere® monotherapy would suitable treatment option ) select basis license use 60-100 mg/m² Taxotere® . The randomised crossover design choose reduce effect intersubject variation . Since Hospira Docetaxel Injection administer man information risk associate clinical use . However active ingredient Hospira Docetaxel Injection Taxotere® expect Hospira Docetaxel Injection exhibit similar safety tolerability profile . An estimated 24 patient recruited several United Kingdom sit one Russian site provide 19 evaluable patient</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Written inform consent give ; Have medically document cancer Taxotere® monotherapy would suitable treatment option ; Aged ≥18 year ; Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ( inclusive ) ; Haematological serum chemical parameter comply follow criterion ( base local laboratory normal reference range ) : Haemoglobin ≥9.5 g/dL Leukocytes ≥3.0 x 10^9/L Neutrophils ≥1.5 x 10^9/L Platelets ≥100 x 10^9 L Total bilirubin ≤2.0 x Upper Limit Normal ( ULN ) Aspartate aminotransferase ( AST ) ≤2.5 x ULN Alanine aminotransferase ( ALT ) ≤2.5 x ULN Alkaline phosphatase ≤4.0 x ULN Serum creatinine ≤1.5 x ULN Willing use effective method contraception , i.e . intrauterine device ( IUD ) , oral contraceptive , subdermal implant double barrier ( condom contraceptive sponge contraceptive suppository ) , unless anatomically sterile , screen least 12 week last dose Investigational Medicinal Product . Willing able comply requirement protocol available plan duration study . Concomitant treatment cytotoxic agent ; Concomitant use compound induce , inhibit metabolize cytochrome P450 , e.g . ciclosporin , ketoconazole , erythromycin , St John 's Wort ; History presence clinically significant finding , opinion Investigator , would preclude inclusion study ; Clinically significant vital sign 12lead electrocardiogram ( ECG ) result , judged Investigator ; Participation clinical trial use Investigational Medicinal Product within previous month History Hepatitis B Virus , Hepatitis C Virus Human Immunodeficiency Virus ; Recent clinically significant history drug alcohol abuse ; Insulindependent unstable Diabetes Mellitus ; History severe hypersensitivity reaction Taxotere® drug formulate Polysorbate 80 ; History reaction drug contain polyethylene glycol 300 ( PEG 300 ) ; Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Docetaxel</keyword>
	<keyword>Phase I</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Bioequivalence</keyword>
</DOC>